Entrada Therapeutics (TRDA) CFO executes planned stock sale

Rhea-AI Filing Summary

Entrada Therapeutics Chief Financial Officer Kory James Wentworth sold 7,988 shares of common stock in an open-market transaction. The sale occurred on March 4, 2026 at a weighted average price of $12.2549 per share, with individual trade prices ranging from $11.80 to $12.57.

The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the executive on March 6, 2025. Following this sale, Wentworth directly holds 137,987 shares of Entrada Therapeutics common stock.

Insider Trade Summary

Net Seller: 7,988 shares ($97,892)

Net Sell 1 txn

Insider WENTWORTH KORY JAMES

Role Chief Financial Officer

Sold 7,988 shs ($98K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,988	$12.2549	$98K

Holdings After Transaction: Common Stock — 137,987 shares (Direct)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WENTWORTH KORY JAMES

(Last) (First) (Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		S(1)		7,988	D	$12.2549(2)	137,987	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.80 to $12.57, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Entrada Therapeutics (TRDA) report for its CFO?

Entrada Therapeutics reported that CFO Kory James Wentworth sold 7,988 common shares. The open-market sale occurred on March 4, 2026 under a Rule 10b5-1 trading plan, reflecting a pre-scheduled disposition rather than an opportunistic trade.

How many Entrada Therapeutics (TRDA) shares did the CFO sell and at what price?

The CFO sold 7,988 Entrada Therapeutics common shares at a weighted average price of $12.2549. According to the disclosure, the individual trades were executed between $11.80 and $12.57 per share in the open market.

Is the Entrada Therapeutics (TRDA) CFO sale part of a Rule 10b5-1 trading plan?

Yes, the CFO’s sale was executed under a Rule 10b5-1 trading plan. The plan was adopted on March 6, 2025, allowing pre-arranged trading of shares according to predetermined instructions, which can reduce the appearance of discretionary timing.

How many Entrada Therapeutics (TRDA) shares does the CFO hold after the sale?

After the March 4, 2026 transaction, the CFO directly owns 137,987 shares. This figure reflects his remaining direct common stock position following the 7,988-share open-market sale disclosed in the Form 4 filing.

What price range did the Entrada Therapeutics (TRDA) CFO’s share sales cover?

The reported sales were executed at prices between $11.80 and $12.57 per share. The filing states that the weighted average sales price was $12.2549 and that detailed trade-level pricing information is available upon request.

What does a Form 4 filing like this mean for Entrada Therapeutics (TRDA) investors?

This Form 4 shows a scheduled share sale by the CFO under a Rule 10b5-1 plan. It documents insider activity and remaining ownership, offering transparency into executive holdings without necessarily signaling a change in the company’s fundamentals.